Management of the Axilla

Surgical Clinics of North America

Volumn 93, Issue 2, 2013, Pages 429-444

  Zarebczan Dull, Barbara ^a   Neuman, Heather B ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

ACOSOG Z0011; Axillary lymph node dissection; Breast cancer; Micrometastases; Sentinel lymph node

Indexed keywords

ADJUVANT CHEMOTHERAPY; AXILLA; AXILLARY LYMPH NODE EXTIRPATION; BREAST DISEASE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; MICROMETASTASIS; MORBIDITY; NOMOGRAM; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY;

EID: 84875330824     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2012.12.008     Document Type: Review

References (91)

1. Fisher B., Bauer M., Wickerham D.L., et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983, 52:1551-1557.
2. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer 1977, 39:456-466.
3. Giuliano A.E., Dale P.S., Turner R.R., et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995, 222:394-399. [discussion: 399-401].
4. Krag D.N., Weaver D.L., Alex J.C., et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993, 2:335-339. [discussion: 40].
5. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998, 339:941-946.
6. Veronesi U., Paganelli G., Viale G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
7. Zavagno G., De Salvo G.L., Scalco G., et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008, 247:207-213.
8. Krag D.N., Anderson S.J., Julian T.B., et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010, 11:927-933.
9. Mansel R.E., Fallowfield L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98:599-609.
10. Veronesi U., Viale G., Paganelli G., et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251:595-600.
11. Giuliano A.E., Hawes D., Ballman K.V., et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011, 306:385-393.
12. Posther K.E., McCall L.M., Blumencranz P.W., et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg 2005, 242:593-599. [discussion: 599-602].
13. Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8:881-888.
14. Lucci A., Kelemen P.R., Miller C., et al. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 2001, 192:453-458.
15. Morrow M., Rademaker A.W., Bethke K.P., et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery 1999, 126:714-720. [discussion: 720-2].
16. Klimberg V.S., Rubio I.T., Henry R., et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999, 229:860-864. [discussion: 4-5].
17. Rodier J.F., Velten M., Wilt M., et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol 2007, 25:3664-3669.
18. Del Bianco P., Zavagno G., Burelli P., et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol 2008, 34:508-513.
19. Wilke L.G., McCall L.M., Posther K.E., et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006, 13:491-500.
20. Lucci A., McCall L.M., Beitsch P.D., et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25:3657-3663.
21. Ashikaga T., Krag D.N., Land S.R., et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010, 102:111-118.
22. Wernicke A.G., Shamis M., Sidhu K.K., et al. Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance. Am J Clin Oncol 2013, 36(1):12-19.
23. Burak W.E., Goodman P.S., Young D.C., et al. Seroma formation following axillary dissection for breast cancer: risk factors and lack of influence of bovine thrombin. J Surg Oncol 1997, 64:27-31.
24. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000, 18:2553-2559.
25. Schrenk P., Rieger R., Shamiyeh A., et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000, 88:608-614.
26. Gill G., SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009, 16:266-275.
27. Lyman G.H., Giuliano A.E., Somerfield M.R., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23:7703-7720.
28. American Society of Breast Surgeons guidelines for performing sentinel lymph node biopsy in breast cancer. 2010. Available at:. Accessed July 10, 2012. http://https://www.breastsurgeons.org/statements/2010-Nov-05_Guidelines_on_Performing_SLN.pdf.
29. Krontiras H., Bland K.I. When is sentinel node biopsy for breast cancer contraindicated?. Surg Oncol 2003, 12:207-210.
30. Pandit-Taskar N., Dauer L.T., Montgomery L., et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006, 47:1202-1208.
31. Wiatrek R., Kruper L. Sentinel lymph node biopsy indications and controversies in breast cancer. Maturitas 2011, 69:7-10.
32. Klauber-DeMore N., Tan L.K., Liberman L., et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?. Ann Surg Oncol 2000, 7:636-642.
33. Goyal A., Douglas-Jones A., Monypenny I., et al. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat 2006, 98:311-314.
34. Port E.R., Garcia-Etienne C.A., Park J., et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol 2007, 14:2209-2214.
35. Knauer M., Konstantiniuk P., Haid A., et al. Multicentric breast cancer: a new indication for sentinel node biopsy: a multi-institutional validation study. J Clin Oncol 2006, 24:3374-3380.
36. Tousimis E., Van Zee K.J., Fey J.V., et al. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J Am Coll Surg 2003, 197:529-535.
37. Gentilini O., Veronesi P., Botteri E., et al. Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution. Ann Surg Oncol 2011, 18:2879-2884.
38. Goyal A., Newcombe R.G., Mansel R.E., et al. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004, 30:475-479.
39. Chung M.H., Ye W., Giuliano A.E. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 2001, 8:688-692.
40. Wong S.L., Chao C., Edwards M.J., et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg 2001, 67:522-526. [discussion: 7-8].
41. Bedrosian I., Reynolds C., Mick R., et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000, 88:2540-2545.
42. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996, 276:1818-1822.
43. Giuliano A.E., Hunt K.K., Ballman K.V., et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
44. Giuliano A.E., McCall L., Beitsch P., et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252:426-432. [discussion: 32-3].
45. de Boer M., van Deurzen C.H., van Dijck J.A., et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009, 361:653-663.
46. Weaver D.L., Ashikaga T., Krag D.N., et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011, 364:412-421.
47. American Society of Breast Surgeons position statement on management of the axilla in patients with invasive breast cancer. 2011. Available at:. Accessed July 6, 2012. http://https://www.breastsurgeons.org/statements/PDF_Statements/Axillary_Management.pdf.
48. Land S.R., Kopec J.A., Julian T.B., et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 2010, 28:3929-3936.
49. Montgomery L.L., Thorne A.C., Van Zee K.J., et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg 2002, 95:385-388. table of contents.
50. Soran A., D'Angelo G., Begovic M., et al. Breast cancer-related lymphedema: what are the significant predictors and how they affect the severity of lymphedema?. Breast J 2006, 12:536-543.
51. Goyal A., Newcombe R.G., Chhabra A., et al. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol 2008, 15:262-267.
52. van Bemmel A.J., van de Velde C.J., Schmitz R.F., et al. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol 2011, 37:829-835.
53. Roses D.F., Brooks A.D., Harris M.N., et al. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999, 230:194-201.
54. Purushotham A.D., Upponi S., Klevesath M.B., et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005, 23:4312-4321.
55. Fleissig A., Fallowfield L.J., Langridge C.I., et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006, 95:279-293.
56. Petrek J.A., Senie R.T., Peters M., et al. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001, 92:1368-1377.
57. McLaughlin S.A., Wright M.J., Morris K.T., et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol 2008, 26:5220-5226.
58. McLaughlin S.A., Wright M.J., Morris K.T., et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008, 26:5213-5219.
59. Herd-Smith A., Russo A., Muraca M.G., et al. Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer 2001, 92:1783-1787.
60. Liljegren G., Holmberg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997, 33:193-199.
61. Erickson V.S., Pearson M.L., Ganz P.A., et al. Arm edema in breast cancer patients. J Natl Cancer Inst 2001, 93:96-111.
62. Paskett E.D., Naughton M.J., McCoy T.P., et al. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2007, 16:775-782.
63. Kiel K.D., Rademacker A.W. Early-stage breast cancer: arm edema after wide excision and breast irradiation. Radiology 1996, 198:279-283.
64. Neuman H., Ollila D. Sentinel lymph node biopsy controversy: before or after chemotherapy. Curr Breast Cancer Rep 2009, 1(2):71-77.
65. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
66. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
67. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, (30):96-102.
68. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194.
69. van der Hage J.A., van de Velde C.J., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19:4224-4237.
70. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005, 23:2694-2702.
71. Hunt K.K., Le-Petross H.T., Suman V., et al. A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071. J Clin Oncol 2010, 28:15s.
72. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002, 347:567-575.
73. Spruit P.H., Siesling S., Elferink M.A., et al. Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol 2007, 2:40.
74. Hwang R.F., Gonzalez-Angulo A.M., Yi M., et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 2007, 110:723-730.
75. Straver M.E., Meijnen P., van Tienhoven G., et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010, 17:1854-1861.
76. Kuehn T., Santjohanser C., Grab D., et al. Endoscopic axillary surgery in breast cancer. Br J Surg 2001, 88:698-703.
77. Langer I., Kocher T., Guller U., et al. Long-term outcomes of breast cancer patients after endoscopic axillary lymph node dissection: a prospective analysis of 52 patients. Breast Cancer Res Treat 2005, 90:85-91.
78. Hussein O., El-Nahhas W., El-Saed A., et al. Video-assisted axillary surgery for cancer: non-randomized comparison with conventional techniques. Breast 2007, 16:513-519.
79. Ponzone R., Mininanni P., Cassina E., et al. Axillary reverse mapping in breast cancer: can we spare what we find?. Ann Surg Oncol 2008, 15:390-391. [author reply: 2-3].
80. Thompson M., Korourian S., Henry-Tillman R., et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007, 14:1890-1895.
81. Nos C., Lesieur B., Clough K.B., et al. Blue dye injection in the arm in order to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissection. Ann Surg Oncol 2007, 14:2490-2496.
82. Boneti C., Korourian S., Diaz Z., et al. Scientific Impact Award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg 2009, 198:482-487.
83. Vassallo P., Wernecke K., Roos N., et al. Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US. Radiology 1992, 183:215-220.
84. Deurloo E.E., Tanis P.J., Gilhuijs K.G., et al. Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 2003, 39:1068-1073.
85. Abe H., Schmidt R.A., Kulkarni K., et al. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsy-clinical experience in 100 patients. Radiology 2009, 250:41-49.
86. Yang W.T., Metreweli C., Lam P.K., et al. Benign and malignant breast masses and axillary nodes: evaluation with echo-enhanced color power Doppler US. Radiology 2001, 220:795-802.
87. Houssami N., Ciatto S., Turner R.M., et al. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011, 254(2):243-251.
88. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140-1151.
89. Kohrt H.E., Olshen R.A., Bermas H.R., et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008, 8:66.
90. Unal B., Gur A.S., Ahrendt G., et al. Can nomograms predict non-sentinel lymph node metastasis after neoadjuvant chemotherapy in sentinel lymph node-positive breast cancer patients?. Clin Breast Cancer 2009, 9:92-95.
91. Mittendorf E.A., Hunt K.K., Boughey J.C., et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012, 255:109-115.